Frisch Financial Group’s Moderna MRNA Stock Holding History

Frisch Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-890	Closed	-$226K	–	149
2021 Q4	$226K	Sell	890 -170	-16%	-$49.7K	0.07%	144
2021 Q3	$408K	Buy	+1,060	New	+$391K	0.14%	88

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Frisch Financial Group's MRNA Position: Q1 2022 in Review

Frisch Financial Group sold out of Moderna (MRNA) in Q1 2022, closing a stake of 890 shares — an estimated $226K sold.

Frisch Financial Group first reported a position in MRNA in Q3 2021 and held it in 2 quarters. The position peaked at $408K in Q3 2021. 1,007 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

Frisch Financial Group reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
Frisch Financial Group sold 890 Moderna shares in Q1 2022, an estimated $226K.
Frisch Financial Group first reported a position in Moderna in Q3 2021 and held it in 2 quarters.
Frisch Financial Group's Moderna position peaked at $408K in Q3 2021.
1,007 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Frisch Financial Group's 13F filing for Q1 2022, filed 10 May 2022.